Open AccessOral Adverse Events Associated with Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: A Structured Literature Review
Author(s) -
BoersDoets Christine B.,
Epstein Joel B.,
RaberDurlacher Judith E.,
Ouwerkerk Jan,
Logan Richard M.,
Brakenhoff Jan A.,
Lacouture Mario E.,
Gelderblom Hans
Publication year - 2012
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2011-0111
Subject(s) - dysgeusia , medicine , mucositis , adverse effect , stomatitis , everolimus , sorafenib , sunitinib , temsirolimus , dermatology , clinical trial , rash , oncology , renal cell carcinoma , pi3k/akt/mtor pathway , radiation therapy , discovery and development of mtor inhibitors , apoptosis , biochemistry , chemistry , hepatocellular carcinoma
Learning Objectives After completing this course, the reader will be able to: Describe the oral manifestations that can appear with TKI/mTORI. Describe the limitations of the current oral assessment tools in assessing these novel presentations and list items needed to assess the presentations properly.This article is available for continuing medical education credit at CME.TheOncologist.comBackground. Oral adverse events (OAEs) associated with multitargeted tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin inhibitors (mTORIs) are underestimated but frequent and novel presentations of mucosal manifestations. Because optimal antitumor activity requires maintaining the optimal dose, it is essential to avoid unintended treatment delays or interruptions. Methods. We review the reported prevalence and appearance of OAEs with TKIs and mTORIs and the current oral assessment tools commonly used in clinical trials. We discuss the correlations between OAEs and hand–foot skin reaction (HFSR) and rash. Results. The reported prevalence of oral mucositis/stomatitis of any grade is 4% for pazopanib, 28% for sorafenib, 38% for sunitinib, 41% for temsirolimus, and 44% for everolimus. Oral lesions associated with these agents have been reported to more closely resemble aphthous stomatitis than OM caused by conventional agents. In addition, these agents may result in symptoms such as oral mucosal pain, dysgeusia, and dysphagia, in the absence of clinical lesions. Because of these factors, OAEs secondary to targeted agents may be underreported. In addition, a correlation between OAEs and HFSR was identified. Conclusions. OAEs caused by TKIs and mTORIs may represent dose‐limiting toxicities, especially considering the fact that even low grades of OAEs may be troubling to the patient. We discuss how these novel AEs can be assessed because current mucositis assessment tools have limitations. Prospective studies investigating the pathogenesis, risk factors, and management of OAEs are needed in order to minimize the impact on patient's health‐related quality of life.